Gilles de la Tourette syndrome (TS) is characterized by tics, which are transiently worsened by stress, acute administration of dopaminergic drugs, and by subtle deficits in motor coordination and sensorimotor gating. It represents the most severe end of a spectrum of tic disorders that, in aggregate, affect ∼5% of the population. Available treatments are frequently inadequate, and the pathophysiology is poorly understood. Postmortem studies have revealed a reduction in specific striatal interneurons, including the large cholinergic interneurons, in severe disease. We tested the hypothesis that this deficit is sufficient to produce aspects of the phenomenology of TS, using a strategy for targeted, specific cell ablation in mice. We achieved ∼50% ablation of the cholinergic interneurons of the striatum, recapitulating the deficit observed in patients postmortem, without any effect on GABAergic markers or on parvalbuminexpressing fast-spiking interneurons. Interneuron ablation in the dorsolateral striatum (DLS), corresponding roughly to the human putamen, led to tic-like stereotypies after either acute stress or D-amphetamine challenge; ablation in the dorsomedial striatum, in contrast, did not. DLS interneuron ablation also led to a deficit in coordination on the rotorod, but not to any abnormalities in prepulse inhibition, a measure of sensorimotor gating. These results support the causal sufficiency of cholinergic interneuron deficits in the DLS to produce some, but not all, of the characteristic symptoms of TS.
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Tourette sydrome | basal ganglia | interneurons | acetylcholine | animal models G illes de la Tourette syndrome (TS) represents the most severe end of a spectrum of tic disorders that, in aggregate, affect 5% of the population and produce substantial morbidity (1) . Existing treatments are of limited efficacy in severe disease (2) . The defining symptoms of TS are motor and phonic tics, defined as sudden, repetitive, nonrhythmic, involuntary or semiinvoluntary movements or utterances that involve discrete muscle groups. Tics fluctuate and are exacerbated by stress (3) (4) (5) and by acute challenge with prodopaminergic drugs (6) . Individuals with TS also often have deficits in fine motor control (7, 8) , procedural learning (9) , and sensorimotor gating (10, 11) .
Convergent evidence implicates the corticobasal ganglia circuitry in the pathophysiology of TS, although details remain poorly understood (12, 13) . The input nucleus of the basal ganglia, the striatum, receives glutamatergic projections from the cortex and thalamus. The striatum is reduced in volume in individuals with TS (12) (13) (14) , and this reduction predicts the severity and the persistence of symptoms (15) . Whereas the cellular architecture of the dorsal striatum is fairly uniform throughout its medial-lateral extent, the topographic organization of cortical afferents leads to functional segregation among subregions (16) (17) (18) (19) . The dorsolateral striatum (DLS), which corresponds roughly to the human putamen, has been associated with sensorimotor habits (20) and with tic-like stereotypies in rodents (21, 22) . Functional neuroimaging has correlated abnormalities in these lateral corticostriatal networks with tic characteristics in patients with TS, whereas abnormalities in medial networks correlated instead with comorbid obsessive-compulsive symptoms (23) .
The principal cells of the striatum, the GABAergic medium spiny neurons (MSNs), are modulated by several types of interneuron (24) . Recent postmortem work has revealed that specific interneuron populations are abnormal in patients with severe, refractory TS (25) (26) (27) . Cholinergic interneurons, identified by their expression of choline acetyltransferase (ChAT), are critical regulators of striatal function, although they constitute only about 1% of all neurons in the striatum (24) . They are reduced by ∼50% throughout the dorsal striatum in TS (26, 27) . Abnormalities in ChAT interneurons in the ventral striatum have been reported in schizophrenia (28) , but deficits in the dorsal striatum (the caudate and putamen) have only been described in TS (26) .
However, the relationship of this interneuronal deficit to the etiopathophysiology of TS remains unclear. One possibility is that this deficit is causally related to symptoms; ChAT interneuron abnormalities in different striatal subregions may have dissociable contributions to symptomatology. Alternative possibilities include that the ChAT deficit observed in postmortem tissue is a compensation for the primary pathology, a consequence of treatment, or an epiphenomenon of no relevance to symptomatology. Finally, the ChAT interneuron deficit may be pathophysiologically
Significance
Tic disorders, such as Tourette syndrome, are common but poorly understood. Postmortem studies have revealed the loss of a particular subset of neurons, the large cholinergic interneurons, in the caudate and putamen in severe disease. To test whether this neuronal loss leads to disease we turned to studies in mice, where questions of causality are more readily addressed. We developed a strategy for targeted ablation of these interneurons. Their disrupting in the dorsolateral striatumroughly analogous to the putamen-produced abnormal tic-like movements after either acute stress or amphetamine treatment. This demonstrates, for the first time to our knowledge, that the loss of specific interneurons can cause behavioral changes in an animal model that resemble aspects of a movement disorder.
important, but it may manifest only in the context of other pathology, such as the deficit in parvalbumin-expressing interneurons that has also been documented in postmortem tissue (25, 26) , or only through its secondary effects on the functions of striatal circuits during development. Such questions cannot readily be addressed by observational studies in patients.
Therefore, to test the hypothesis that ChAT interneuron disruption in the dorsal striatum is sufficient to produce tic-like phenomenology, we turned to a mouse model. We found an immunotoxin that has been used previously to target striatal ChAT interneurons (29) (30) (31) (32) to produce nonspecific effects (Fig.  S1 ). We therefore developed an approach to induce targeted, regulated ablation of ChAT interneurons in mice. We anticipated that interneuronal abnormalities in different parts of the circuitry might contribute differentially to the TS phenotype. We targeted the ChAT interneurons of the DLS and dorsomedial striatum (DMS) in separate experiments, achieving a ∼50% reduction, which recapitulates the degree of abnormality found postmortem (26) . We tested the effect of this targeted ablation on behavioral phenotypes that recapitulate core phenomenology of TS and that have been found to be abnormal in other animal models (10, 33) . This ChAT ablation does not recapitulate all documented cellular abnormalities in TS (25, 26) or their developmental course, which is not well established. Rather, it tests sufficiency of an isolated ChAT interneuronal deficit in an otherwise normal adult brain to produce aspects of TS phenomenology.
Results
Viral Targeting of Interneurons. We designed a recombinant virus (A06) (Fig. 1A and Materials and Methods) to permit the specific expression of the simian diphtheria toxin receptor (DTR) in creexpressing cells. This makes those cells specifically susceptible to ablation after systemic administration of diphtheria toxin (DT). This virus, and the negative control virus C06 (Materials and Methods), were injected into the dorsal striatum of ChAT-cre transgenic mice (www.jax.org: 006410); mice were euthanized 2 wk later. EGFP expression was seen throughout the striatum, confirming the spread of the rh10 viral serotype and the utility of eGFP as a marker of viral infection. FLAG immunoreactivity was seen only in cells also immunoreactive for ChAT ( Fig. 2A) . No FLAG immunoreactivity was ever seen after C06 injection (Fig. 2B ) or when either virus was injected into wild-type mice.
To test interneuron ablation, we injected A06 virus into the dorsal striatum on one side and C06 into the contralateral dorsal striatum in ChAT-cre transgenic mice. Two weeks later, mice were injected i.p. with either DT (15 μg/kg body weight) or saline. One week after DT injection, ChAT immunoreactive cells were reduced on the A06-infected side relative to the C06 infected side (Fig. 2C) , confirming interneuron ablation. The image shown here is taken from the center of the virus-infused area, where viral infection was highest and ablation was greatest; we achieved ∼50% reduction of the density of ChAT-expressing interneurons in the dorsal striatum more broadly (see below, Fig.  3 B and E), recapitulating the degree of deficit observed in postmortem material from patients (26) .
The ChAT interneuron-specific genes ChAT and Slc5A7 (the choline transporter) showed a ∼50% reduction in A06-infected striatum, compared with C06-infected striatum, after DT ( Fig.  2D and Table S1 ). Glutamic acid dehydrogenase (a marker of GABAergic cells) and the potassium channel KCNC1 (which is expressed in parvalbumin-containing interneurons) were not reduced by ChAT interneuron ablation (Fig. 2D ). Immunostaining for parvalbumin-containing interneurons showed normal numbers of these interneurons (Fig. 2E ).
Tic-Like Stereotypies After ChAT Interneuron Ablation. We characterized behavioral phenotypes that parallel different domains of TS symptomatology (10, 33) following ∼50% ChAT interneuron ablation in the DLS (Fig. 3 A and B and Figs. S2 and S3).
ChAT-ablated mice did not exhibit detectable tic-like stereotypy at baseline. In this way they resemble a recently described genetic model, in which increased tic-like stereotypies only emerged after pharmacological challenge (10) . To test the ability of an acute stressor to potentiate tic-like stereotypies (3-6, 34), we exposed ChAT-ablated animals (and C06-injected controls) to repeated unpredictable acoustic startle stimuli. Grooming, stereotypy, and other behaviors were observationally scored from video before, during, and after this block of startle stimuli. ChATablated mice exhibited no behavioral abnormalities before the stressor, but increased grooming during and after the 11-min startle block (Fig. 3C) . Grooming was fragmented, consisting primarily of repeated initiation of grooming of the face and whiskers, and progressing only infrequently to a full syntactic grooming chain encompassing the whole body; in this it qualitatively resembles the abnormal grooming seen (in the absence of an acute stressor) in mice with a deletion of the SAPAP3 gene (Movie S1) (35) . These abnormal grooming bouts were not timelocked to startle stimuli but rather occurred continuously throughout the startle block and poststartle period.
To test the anatomical specificity of this phenomenon, we performed an otherwise identical ablation in the DMS, in a separate cohort of mice ( Fig. 3 D and E and Figs. S2 and S3). The efficiency of ablation in the DMS was similar to that in the DLS. Mice with ChAT ablation in the DMS showed no alteration in acute stressinduced repetitive grooming (Fig. 3F) .
We also measured locomotor activity and stereotypy before and after i.p. injection of D-amphetamine (10) . The dose (7 mg/kg) was empirically determined in pilot experiments to produce limited stereotypy in intact mice on this genetic background. Both DLS ablation and control groups showed locomotor activation following amphetamine challenge, with no difference between ChAT-ablated and control animals (Fig. 4A ). To maximize throughput and objectivity in the initial analysis of stereotypy, we scored repetitive low-amplitude movements using an automated system (36) . These movements, scored as "grooming" by the automated system, differed across groups, lasting longer and reaching higher levels following amphetamine administration in the ChAT-ablated animals [ Fig. 4B ; time × treatment interaction, F(11, 99) = 2.02, P = 0.034]. To confirm the phenotype, a rater blind to experimental condition manually scored stereotypy at all time points in the second half hour after amphetamine, where automated scoring indicated a separation between groups, for post hoc analysis. Manual and automated scoring correlated significantly, although imperfectly, across this time period (Fig. 4C) . Manual scoring confirmed greatly increased stereotypies in ChAT-ablated mice, across all measured time points (Fig. 4 D and  E) . Qualitatively, these stereotypies consisted primarily of focused repetitive sniffing (Movie S2), similar to those observed in a recently described genetic animal model of TS, the histidine decarboxylase knockout mouse (10) .
After amphetamine, DMS ChAT-ablated mice showed slightly enhanced locomotor activation, relative to controls (Fig. 4F) , and no change in stereotypy (Fig. 4G) , confirming a dissociable role for DLS and DMS in the generation of tic-like phenomenology after ChAT interneuron ablation.
Other TS-Relevant Behavioral Phenotypes. We tested DLS ChATablated mice and found no prepulse inhibition (PPI) deficit (Fig.  S4A) . Excitotoxic DMS lesions impair PPI (37); however, we also found no PPI deficit after DMS ChAT ablation (Fig. S4B) .
Patients with TS also exhibit deficits in certain fine motor skills (7, 8) . We tested ChAT-ablated mice on the rotorod, which assays both baseline motor performance and improvement over time. Mice with a DLS ChAT lesion showed a marked deficit in baseline rotorod performance (Fig. 5A ) but rapidly improved with training to a level of performance indistinguishable from controls ( Fig. 5B) . DMS ChAT-lesioned mice showed no deficits either at baseline or across trials ( Fig. 5 C and D) .
ChAT-ablated mice and control mice showed similar activity in the open field and similar anxiety-like behaviors in both the open field and the elevated plus maze (Figs. S5 and S6).
Discussion
The etiology and pathophysiology of TS are not well understood (13) . Postmortem studies show a reduction in ChAT-expressing striatal interneurons in the caudate and putamen in individuals with severe, refractory disease (26, 27) . However, such correlational findings cannot elucidate the causal role of this cellular deficit: whether it is pathogenic, compensatory, epiphenomenomenal, or a marker of a more complex developmental disruption.
We have examined this question by producing a similar deficit in ChAT interneurons in the dorsal striatum of otherwise normal adult mice. Targeted cell ablation in the adult does not, of course, recapitulate the developmental consequences of a ChAT deficit and potential abnormal local connectivity that may accompany congenital pathology; rather, it examines the effects of a ChAT interneuron deficit in an otherwise normally developed striatal circuitry. Previous studies have examined effects of ChAT ablation in the nucleus accumbens (31, 32) , or more broadly throughout the striatum (29), but they have not discriminated between DLS and DMS, have not systematically tested for TS-associated behavioral effects, and have relied on immunotoxins that we find to have nonspecific effects (Fig. S1 ). Our results establish the sufficiency of ChAT interneuron disruption in the dorsolateral striatum in the adult to recapitulate some aspects of TS, although not all. This argues in favor of a direct role for the ChAT deficit in pathophysiology, and against a compensatory or epiphenomenal one. Some aspects of TS, such as the premonitory urges that often precede tics, are difficult or impossible to assess in an animal (3) (4) (5) ; but behaviors recapitulating aspects of the motor symptomatology are accessible in mice (10) . Low-amplitude, stereotyped, repetitive movements that recapitulate aspects of tics can be quantified; these include excessive and fragmentary grooming (35, 38) and motor stereotypy (10, 39, 40) . Other aspects of TS symptomatology can be captured using PPI and with tests of motor coordination and learning (33) .
We see tic-like stereotypy only after DLS ChAT ablation, not after DMS ChAT ablation (16, 17) . In postmortem material from patients with TS, the ChAT interneuron loss is prominent in dorsal striatum (both associative and sensorimotor territory) and not seen in the ventromedial striatum (limbic territory) (26). Our results suggest that tics may relate specifically to deficits in the lateral/sensorimotor striatum and not to those in the more medial, associative circuitry. This is consistent with the role of the DLS in stereotypy and in habit learning in other contexts (20) (21) (22) 41) , and with findings of increased functional connectivity in the putamen to correlate with tic complexity (23) . It is possible that dorsomedial pathology relates to other aspects of pathology, such as obsessive-compulsive symptoms (23) , that are not readily captured by our behavioral assays in mice.
We observe manifest stereotypy only after stress or amphetamine challenge. This may be simply a matter of assay sensitivity; any quantification of stereotypy, automated or manual, is of limited sensitivity and may miss low-amplitude movements. Alternatively, it may be related to the fact that our ablation occurs in adulthood and thus incompletely recapitulates the relevant pathology. It may also be the case that ChAT deficiency is one of several insults that can destabilize the corticostriatal system, and that more than one such pathophysiological "hit," such as pathology in other populations of interneuron (25, 26) , developmental stress, or immune challenge (13) , is required for spontaneous tic-like movements to emerge. It should be noted that the individuals studied in the postmortem study on which our experiment is based (26) had particularly severe disease that persisted into adulthood and remained prominent despite attempts at treatment. It is possible that the ChAT deficit we are modeling here is specific to such refractory cases and would not be seen in treatment-responsive or developmentally remitting TS. The examination of such severe cases may nevertheless shed light on pathophysiological mechanisms that are shared with more typical disease. It might be, for example, that ChAT neurons are dysfunctional but not absent in milder disease and that compensatory optimization of their function is a mechanism for symptom improvement over the course of development.
We have described the repeated unpredictable presentation of a loud acoustic startle stimulus (Fig. 3) as an acute stressor. Both acute and chronic stressors can accentuate tic symptomatology in individuals with TS (3-5). We have not objectively measured other correlates of stress, such as corticosterone levels, and other interpretations of the mechanism by which the repeated startle stimuli produced enhanced and fragmented grooming stereotypies are possible. For example, startle stimuli can themselves in some cases trigger or potentiate tics (42, 43) . However, the stereotypies we observe were not phasically entrained to the presentation of startle stimuli; rather, they occurred intermittently throughout and after the period of startle stimulus presentation (Movie S1 and Fig.  3) . Irrespective of the specific underlying mechanism, this paradigm clearly illustrates increased tic-like stereotypies after ChAT interneuron ablation, in the absence of a pharmacological challenge.
The cause of the slight enhancement of amphetamine-induced locomotion after DMS ChAT ablation, and its relevance to TS, is unclear. It is noteworthy that the most medial portion of the rodent dorsal striatum is functionally related to the ventral striatum/ nucleus accumbens, in which a ChAT deficit has been documented in schizophrenia (28) but not in TS (26) .
The effects of ChAT ablation in the DLS on striatal neurochemistry and information processing remain to be explored in detail. Cholinergic interneurons, also termed "tonically active neurons," have a role in the modulation of striatal dopamine dynamics (44, 45) ; disruption of dopamine (DA) may therefore underlie the observed effects (13) . However, ChAT interneurons also regulate both other populations of striatal interneurons and the MSNs themselves; a ChAT deficit may therefore lead to disorganized striatal information processing, independent of any effect on DA (46) . ChAT interneurons also encode taskrelevant information during reward-motivated contingency learning (47) (48) (49) and mediate the integration of thalamic and cortical afferent information (48, 50) . The disruption of these functions may also contribute to aspects of the symptomatology of TS.
The fact that we see behavioral abnormalities that recapitulate aspects of TS after ChAT interneuron ablation in the adult indicates that a cholinergic deficit in the adult is sufficient to produce TS-relevant consequences. A cholinergic deficit might be pharmacologically mitigated by using cholinesterase inhibitors, which extend the half-life of endogenously released acetylcholine. A few small studies and case reports have attempted this, with some reports of benefit but also with significant side effects (51, 52 ). An alternative is the use of muscarinic or nicotinic cholinergic agonists, although it remains unclear which receptors would optimally be targeted. A few studies suggest that nicotine gum or patch are of little benefit by themselves but can augment that efficacy of haloperidol treatment; side effects again have been limiting in many cases (51) . It should be noted that TS symptoms fluctuate, and therefore that uncontrolled studies are notoriously unreliable; placebo-controlled trials of these therapeutic strategies are needed.
Our work does not address the cause of the cholinergic deficit. The ChAT interneurons may fail to develop or differentiate properly, fail to migrate to the striatum during development, migrate but die without integrating properly into the striatal circuitry, or develop and integrate normally but die (or dedifferentiate) at a later time. Inflammatory damage to them is an interesting possibility, given recent evidence for an elevated inflammatory state in the TS striatum (27, 53) , but this remains speculative. The development of preventative or disease-modifying therapeutics targeting the cholinergic deficit will be facilitated by clarification of its etiology.
This work highlights the potential importance of cholinergic dysregulation to the pathophysiology of TS and establishes a system in which the consequences of this dysregulation, which recapitulates one aspect of the abnormalities documented postmortem (26), can be examined. These results are consistent with an emerging body of evidence suggesting that deep brain stimulation of the intralaminar nuclei of the thalamus, which project to ChAT-positive interneurons in the striatum (50), can be of benefit in severe, intractable TS (54) . It is to be hoped that better understanding of this aspect of the pathophysiology of TS will lead to new treatment options.
Materials and Methods
All experiments were performed in accordance with the NIH's Guide for the Care and Use of Laboratory Animals (55) and were approved by the Yale University Institutional Animal Care and Use Committee. More details are included in SI Materials and Methods.
Immunotoxins. ChAT interneuron ablation in the striatum has been previously performed using proteinaceous toxins coupled to specific antibodies (29-32). Unfortunately, whereas ChAT interneuron ablation was apparent after ChAT-saporin (SAP), we also found reductions in ChAT immunoreactivity, qualitative changes in ChAT cell morphology, and patchy cell loss after treatment with IgG-SAP, even at low doses (Fig. S1 ). This motivated us to design a targeting system for more specific and controlled interneuronal ablation.
Vector Constructs and Validation of Cell Ablation. DT induces apoptosis with extraordinary efficiency (56), but it cannot normally enter rodent cells. Expression of the simian diphtheria toxin receptor (sDTR) renders mouse cells sensitive to ablation after systemic DT (57). We developed a combinatorial approach to restrict sDTR, fused to a flu antigen (FLAG) epitope for ready immunohistochemical identification, to ChAT interneurons of the dorsal striatum. Construct A06 expresses eGFP in cre-negative cells but sDTR in cre-positive cells. The negative control construct, C06, expresses eGFP in all infected cells, irrespective of creexpression (Fig. 1A) . This was confirmed by transient transfection in cultured N2a neuroblastoma cells (Fig. 1B) . The constructs were packaged into AAVrh10 serotype (58) and infused into the dorsal striatum, one on each side, to validate ChAT-specific DTR expression and cell ablation (Fig. 2) .
Quantitative PCR Expression Analysis. Mice were killed 15 d following DT injection (∼30 d following virus infusion), to correspond to the period when behavioral analysis was performed (7-27 d following DT). Brains were rapidly dissected and mRNA isolated; target genes were quantified by RT-PCR.
Behavioral Analysis. For behavioral analysis, virus A06 was infused bilaterally into adult male ChAT-cre mice for ablation; genetically identical littermate control animals received a bilateral infusion of control virus C06. All mice received DT (15 μg/kg) 15 d after surgery; behavioral analysis began 1 wk later and continued for ∼3 wk.
Elevated plus maze, open field exploration, PPI, and rotorod testing were performed as previously described (10, 37, 59) .
Stress-induced stereotypy was measured using an acute stress paradigm, which consisted of the repeated, unpredictable presentation of a loud startle stimulus in a sound-attenuating chamber. Grooming and stereotypies were scored from video by a rater blind to experimental condition.
For amphetamine-induced stereotypy, the amphetamine dose, 7.0 mg/kg, was empirically determined in pilot experiments to be sufficient to produce moderate stereotypies in animals on this genetic background. Stereotypy was initially scored using an automated system (HomeCageScan, www. cleversysinc.com; Fig. 4 B and G) ; confirmatory analysis was performed by manual scoring from video by a scorer blind to experimental condition, as previously described (10).
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Mice were housed in a temperature and climate-controlled facility on a 12-h light/dark schedule. Adult male mice (3-4 mo), backcrossed to >N4 onto C57BL/6, were used in all experiments.
Immunotoxin Ablation. A targeted immunotoxin, ChAT-saporin (ChAT-SAP) (Advanced Targeting Systems, IT-42) and with a negative control, saporin conjugated to nonspecific IgG (IgG-SAP) (Advanced Targeting Systems, IT-35), were infused into the dorsal striatum of male wild-type C57BL/6 mice (The Jackson Laboratories), using standard stereotaxic technique. Target coordinates were anterior-posterior (AP) 0.7 mm, medial-lateral (ML) ± 2.3 mm, dorsal-ventral (DV) −3.5 mm. A total of 0.3 μL of ChAT-SAP was injected into mouse striatum with a dose of 0.3 μg/μL at a flow rate of 0.1 μL/min using 2 μL Hamilton syringe attached to a micropump [UltramicroPump II; World Precision Instruments (WPI)], whereas control mice were equivalently injected with IgG-SAP. Mice were euthanized and their brains rapidly removed 1 wk after the toxin injection. Brains were sliced, equilibrated in a sucrose solution, and sliced on a cryostat. Brain slices were immunostained using goat anti-ChAT primary antibody (Millipore: AB144P) 1:500 and biotinylated rabbit anti-goat Ig secondary antibody (Vector Laboratories; BA-5000) at 1:1,000, followed by diaminobenzidine immunoperoxidase development using the Vectastain Elite ABC kit (Vector Laboratories) and the DAB substrate kit for peroxidase (Vector Laboratories), according to the manufacturer's instructions; immunostaining was performed using rabbit serum.
Unfortunately, whereas ChAT interneuron ablation was apparent after ChAT-SAP, we also found reductions in ChAT immunoreactivity, qualitative changes in ChAT cell morphology, and patchy cell loss after treatment with IgG-SAP, even at low doses (Fig. S1 ). Both ChAT-SAP and IgG-SAP also led to prominent microgliosis throughout the striatum. This calls into question the specificity of such reagents, at least in mice. This motivated us to design a targeting system for more specific and controlled interneuronal ablation.
Vector Constructs and Adeno-Associated Virus Production. Diphtheria toxin (DT) induces apoptosis with extraordinary efficiency (1), but it cannot normally enter rodent cells. Expression of the simian diphtheria toxin receptor (sDTR) renders mouse cells sensitive to ablation after systemic DT (2). We developed a combinatorial approach to restrict sDTR, fused to a flu antigen (FLAG) epitope for ready immunohistochemical identification, to ChAT interneurons of the dorsal striatum (Fig. 1A) .
We used a modified FLEX cassette (Fig. 1A) to invert eGFP and DTR-FLAG in the presence of Cre-recombinase. The promoter/enhancer combination used to drive expression included the elongation factor 1a promoter and the 3′ enhancer woodchuck hepatitis virus posttranscriptional regulatory element. We used a modified FLEX cassette with two pairs of inverted cre-recognition sites (loxP and lox2722) (3) to invert eGFP and DTR-FLAG, and delete eGFP, in the presence of cre-recombinase, such that DTR-FLAG is brought into the sense orientation and is expressed from the EF-1 promoter. Cre-expressing cells are thus made susceptible to ablation by systemic administration of DT (2) . eGFP was inserted in between the loxP and lox 2722 sites at the 5′ end of the FLEX cassette. The simian diphtheria toxin receptor (DTR) gene, labeled at its C-terminal with a flu antigen (FLAG) epitope tag, was placed within the FLEX cassette in the antisense orientation. In the presence of Cre-recombinase this cassette inverts, such that DTR-FLAG is brought into register with the EF-1a promoter, and the eGFP gene is deleted. (We found eGFP deletion to be necessary for optimal DTR expression, presumably because the antisense eGFP gene in the 3′ untranslated region of the DTR mRNA after Cre-mediated flipping interferes with efficient translation.)
This construct expression cassette was packaged into adenoassociated virus (AAV) rh10 serotype by the Salk Institute Viral Vector Core (vectorcore.salk.edu) with a titer of 1 × 10 13 genomic copies per milliliter, as measured by real-time PCR.
We also designed a control vector, C06, as shown in Fig. 1A , which has very similar sequence as A06 but with muptiple point mutations in the 3′ loxP and lox 2722 sites, preventing Cremediated inversion. The sequence below shows with bold letters indicating mutations: ATAACTTCGTATAAAAAAAAATATAC-GAAGTTATTTGCCTTAACCCAGAAATTATCACTGTTAT-TCTTTAGAATGGTGCAAAGAATAACTTCGTATACCCCC-CCCTATACGAAGTTAT. C06-infected cells thus always express eGFP and never express DTR, irrespective of Cre-expression.
In Vitro Transfection. These constructs were tested in vitro using transient transfection. Neuro-2a mouse neuroblastoma cells (ATCC) were cultured in a 12-well plate in complete growth culture media DMEM (Gibco). Transient transfections were performed using Lipofectamine LTX (Life Technologies), following the manufacturer's instructions. For each transfected well, 1 μg DNA and 1 μL PLUS were added to 200 μL Opti-MEM medium, mixed, and incubated at room temperature for 5 min. A total of 4 μL of Lipofectamine LTX was added, and the mixture was allowed to sit for 25 min. The mixture was then added to each well. At 48 h later, cells were rinsed with PBS and fixed with 1% paraformaldehyde/PBS solution at 4°C overnight before immunostaining, as detailed below.
A total of 0.5 μg of each plasmid was used for each transfection. For conditions in which only one plasmid was transfected, an additional 0.5 μg plasmid DNA (pUC) was added, such that a total of 1 μg DNA was used for each transfection. Note that transfected Cre-recombinase was fused to eGFP; green fluorescence in these experiments (Fig. 1B) therefore reflects both eGFP expression from the A06 or C06 construct and Cre-expression.
In Vivo Viral Infusion and Virus Validation. Adult male hemizygous ChAT-cre transgenic mice were produced in our vivarium by crossing heterozygous male Chattm1(cre)Lowl mice (www.jax. org: 006410) with female wild-type C57BL/6 mice (The Jackson Laboratories). Stereotaxic surgery was performed following standard procedures, under sterile conditions. ChAT-cre mice were anesthetized with an i.p. injection of xylazine (10 mg/kg; Bayer Pharma) and ketamine (100 mg/kg; Merial) and placed into a mouse stereotaxic apparatus. A 2-μL Hamilton syringe attached to a micropump (UltramicroPump II; WPI) was lowered through a skull burr hole into the striatum at the coordinates: DLS (AP + 0.8 mm; ML ± 2.3 mm; DV −3.5 mm relative to bregma) or DMS (AP + 0.9 mm; ML ± 1.5 mm; DV −3.5 mm), with reference to the atlas of Paxinos (4) . A total of 0.4 μL (for DLS) or 0.27 μL (for DMS) of virus was infused bilaterally at a flow rate of 0.1 μL/min. The Hamilton syringe was left in place for 10 min after completion of the infusion to eliminate back-flow and then slowly withdrawn. This process was repeated on the other side to produce bilateral viral injections. Mice were then sutured and returned to their home cage for a minimum of 2 wk postsurgery.
For validation experiments (Fig. 2) , mice received A06 virus on one side and C06 contralaterally. Some mice in validation experiments were killed 2 wk later, without administration of DT (Calbiochem, 15 μg/kg i.p.; Fig. 2 A and D) . In all other experiments (Figs. 2 B and C, 3, and 4 ), mice received a single DT i.p. injection at a dose of 15 μg/kg. This dose was empirically determined to produce efficient interneuronal ablation (Figs. 2C and  3 B and E) without any detectable histological or behavioral effects in C06-infused transgenic mice or in wild-type animals. Higher doses (40 μg/kg) impaired animals' startle response in a PPI assay, raising concerns that there might be other nonspecific effects.
A separate cohort of four mice was identically treated for qPCR validation of ChAT interneuron ablation (Fig. 2E) , as further described below.
Immunohistochemistry. Mouse brains were rapidly dissected and fixed overnight in 4% (mass/vol) paraformaldehyde/PBS solution at 4°C. After fixation, brains were equilibrated with 30% (mass/vol) sucrose/PBS. Frozen coronal sections were cut at 40 μm in six continuous slide sets throughout the striatum, such that each set sampled the brain at ∼250-μm intervals, and stored in cryoprotectant solution [30% (vol/vol) glycerin, 30% (vol/vol) ethylene glycol, 0.2× PBS solution] at 4°C. Sections were immunostained following standard protocols. Briefly, brain sections were blocked in PBS with 10% (vol/vol) rabbit or donkey or goat serum, 0.2% Triton X, and 0.1% Tween 20 for 30 min at room temperature. Floating brain sections were stained with primary antibody in 1× PBS, 0.2% Triton X, and 0.1% Tween 20 + 5× rabbit or donkey or goat serum overnight at 4°C, rinsed three times for 10 min with PBS at room temperature, stained with secondary antibody in 1× PBS, 0.2% Triton X, and 0.1% Tween 20 + 10× serum for 1 h at room temperature, and again rinsed three times for 10 min with PBS. Primary antibodies included goat anti-ChAT primary antibody (1:500; Millipore, AB144P), mouse anti-FLAG (1:500; Sigma, F1804), and chicken anti-GFP (1:2,000; Abcam, Ab13970).
For cell counting, ChAT was visualized ( Fig. 3 B and F and Fig.  S3 ) using goat anti-ChAT primary antibody (Millipore, AB144P) 1:500 and biotinylated rabbit anti-goat Ig second antibody (Vector Laboratories, BA-5000) at 1:1,000 followed by diaminobenzidine immunoperoxidase development using the Vectastain Elite ABC kit (Vector Laboratories) and the DAB substrate kit for peroxidase (Vector Laboratories), according to the manufacturer's instructions; immunostaining was performed using rabbit serum. Within each section the boundaries of the striatum were established using anatomical markers (chiefly the internal capsule and other white matter tracks; ref. 4) , and ChAT-positive neurons within striatum were counted bilaterally in each section where this structure was present throughout the series. About five sections per mouse were then examined. Because of the relatively small number of total ChAT interneurons in the striatum, we counted all visible ChAT-positive cells rather than performing a stereological analysis. DMS and DLS were defined by arbitrarily dividing the striatum in two at its midpoint with a dorsal-ventral line. Data reported describe the number of ChAT-positive neurons counted in the DLS (Fig. 3B) or DMS (Fig. 3E) , and demonstrate the extent of depletion of ChAT-positive cells in lesioned mice relative to controls. Cell counting was performed using Stereoinvestigator (MBF Biosciences).
For fluorescent staining ( Figs. 1 and 2 ), primary antibodies were mouse anti-FLAG (1:500; Sigma F1804), chicken anti-GFP (1:2,000; Abcam, Ab13970) and goat anti-ChAT (1:500; Millipore, AB144P). Second antibodies were Alexa Fluor 594-conjugated donkey anti-mouse (1:400; Life Technologies, A21203), Dylight 488-conjugated donkey anti-chicken (1:400; Jackson Immunoresearch, 97336), and Alexa Fluor 633-conjugated donkey anti-goat (1:400; Life Technologies, A21082) were used; staining was performed using donkey serum. For apoptosis staining, rabbit anti-caspase 3 primary antibody (1:1,000; Abcam, AB44974) and Alexa Fluor 594-conjugated goat anti-rabbit (1:400; Life Technologies, A11037) were used, in goat serum. Confocal images (Fig. 2 A-C) were taken using a laser scanning confocal microscope (Olympus Fluoview FV300) at 200×. Fluorescent images (Fig. 1B) were taken with a Zeiss fluorescent microscope.
qPCR Expression Analysis. Mice (n = 4) were killed 15 d following DT injection. Striatum was rapidly dissected on ice. Tissue was stored at −80°C for subsequent RNA isolation. RNA was isolated using the RNeasy Plus Mini kit (Qiagen), according to the manufacturer's instructions. RNA was reverse transcribed using SuperScript III (Life Technologies), and expression levels were evaluated with OneStep qPCR (Applied Biosystems) using SYBR Power Green (Applied Biosystems). GAPDH was used as the reference gene and analysis was performed using the ddCt method. Primer sequences are presented in Table S1 .
Behavioral Analysis. For behavioral analysis, viruses were bilaterally infused into DLS or DMS, using the coordinates above; A06 was infused bilaterally for ablation animals and C06 for control animals. Age-matched male ChAT-cre transgenic mice were randomly assigned to receive either C06 or A06 virus. DT (15 μg/kg) was injected 14-15 d after surgery; behavioral analysis began 1 wk later. All brains were examined histologically after the completion of behavioral experiments, as described below; extent of viral spread ( Fig. 3 A and D and Fig. S2 ) and ChAT interneuron ablation (Fig. 3 B and E and Fig. S3 ) were assayed; animals in which the virus was mistargeted were to be excluded, but no animals had to be excluded from either cohort. In DLS behavioral experiments (Figs. 3 and 4) , n = 5 C06-infused control animals, n = 6 A06-infused ablation animals (after one C06-infused animal died postsurgery). In DMS behavioral experiments (Figs. 3 and 4) , n = 6 C06-infused control animals and n = 7 A06-ablation animals (after one C06-infused animal died postsurgery). This group size was chosen because groups of this size have been sufficient to reveal stereotypy in an independent animal model (5).
Elevated Plus Maze and Open Field. The elevated plus maze test and the open field test were performed as previously described (5). Animals' exploratory activity was recorded using an overhead video camera connected to a computer. The Anymaze video tracking system (Stoelting) was used to measure the time spent in the open arms in 5 min in the elevated plus maze test and the time spend in the center zone and total distance traveled during a 10-min monitoring session in the open field test. The apparatus was thoroughly cleaned with 70% ethanol before each mouse was tested. The data analysis was done with Anymaze software by an investigator blind to experimental condition.
The open field test was done as previously described (6) . Mice were placed into a clean Plexiglass box, 50 cm × 50 cm, with no bedding, under moderate intensity indirect illumination. Locomotor exploratory activity over 10 min was quantified using an overhead camera and the Anymaze video tracking system. Time spent in the central zone (25 cm × 25 cm) was quantified as an additional index of anxiety.
Prepulse Inhibition of Acoustic Startle. PPI was tested in an acoustic startle chamber (San Diego Instruments) using SR Lab startle response software as described previously (5, 7). Each mouse was placed into a Plexiglass cylinder attached to a piezoelectric sensor. The startle response to an acoustic stimulus was measured in the presence of a 65-dB white noise background that began a 5-min acclimation period. Each session consisted of four continuous block designs of a total of 65 trials that presented a 20-ms prepulse of 6, 12, or 16 dB above background white noise followed 200-ms later by either a 40-ms 120-dB startle pulse or no pulse at all (null). Blocks 1 and 4 consisted of six consecutive pulse-alone trials, whereas blocks 2 and 3 each consisted of six pulse-alone trials, five of each kind of prepulse trial, and five no-stimulus trials, intermingled in pseudorandom order. The intertrial interval (ITI) averaged 15 s but was pseudorandomized during presentations. Startle magnitude was calculated as the average response to all of the pulse-alone trials in each block. Percentage of PPI was calculated as a percentage score in startle response caused by presentation of the prepulse according to the following formula: % PPI = 100 − [(mean startle response for prepulse-pulse trial)/(mean startle response for pulse-alone trial)] × 100. Initial analysis was performed blind to experimental condition.
Rotarod. Motor learning was assessed with an Med Associates rotarod machine. The rotation rate was increased from 4 to 40 rpm over 5 min. Five animals were tested concurrently in separate 6-cm-wide compartments, on a rod that was ∼3 cm in diameter and was elevated 16.5 cm. Each animal was assessed over three trials per day with 20-min ITIs and trained for 2 d. Latency to fall from the rod was recorded. Latency to fall in the first trial was analyzed by t test, to assess basal motor function/coordination. Latency to fall across trials was analyzed by RM-ANOVA, to assess motor learning. The investigator performing this experiment was blind to experimental condition.
Startle-Induced Stress. We noted repetitive grooming in ChAT interneuron-ablated animals after PPI during pilot experiments. We therefore used repeated unpredictable presentation of the acoustic startle stimulus as a mild stressor. Mice were placed in a clear-sided Plexiglass box (28 cm × 17 cm × 21 cm) within the sound-attenuating chambers where PPI is performed; the door was left open (for better visual monitoring) and the plastic cylinder within which mice are constrained during PPI was removed. Mice were acclimated to the box for 10 min, then a pseudorandom series of startle stimuli, identical to our PPI protocol (5, 7), was run for 13 min. Mice were visually monitored before, during, and for 30 min after this stressor. The whole process was videotaped and manually scored by an observer blind to experimental condition assignments. Time spent in repetitive behaviors, which consisted primarily of increased grooming, was scaled to a 10-min block for each stage; between-group comparisons were performed by t test.
Amphetamine-Induced Locomotion and Stereotypical Behaviors.
D-amphetamine (AMPH) (Sigma) was dissolved in sterile 0.9% saline and injected intraperitoneally at 7 mg/kg. This dose was found in pilot experiments to be at the threshold for the production of substantial stereotypies in mice of this genetic background and have been selected for its effectiveness in activating locomotor behavior and for its discriminating effects in mouse models reproducing stereotype behavior. Baseline locomotor data and stereotypical behaviors were collected 10 min before AMPH (7 mg/kg, i.p.) treatment and mice were monitored for at least 60 min following injection of AMPH to determine whether mice expressed stereotypy behavior. The whole process was videotaped and automatically scored with the Cleversys system using a side camera, then manually checked by an observer unaware of treatment assignments (Fig. S4C) .
Statistical Analysis. Data were organized using Microsoft Excel and analyzed using SPSS (IBM). No datasets violated normality assumptions; two-tailed parametric statistics were used in all cases, and the threshold for significance was set at alpha = 0.05. Student's t test or repeated-measure ANOVA were used, as appropriate and as described in the text. For repeated-measures behavioral data (Fig. 3 C, D, G, and H) , data are collapsed across 30-min blocks following amphetamine stimulation for presentation and for post hoc analysis; however, the primary analysis used all data in 5-min bins in a repeated-measures ANOVA (Figs. S4 and S5) . . Representative ChAT interneuron distribution in the striatum after DT-mediated ablation. ChAT immunoreactivity was visualized using diaminobenzidine. As there is no anatomical boundary between DLS and DMS, for purposes of quantification we arbitrarily divided the dorsal striatum down the middle, as shown, based on anatomical criteria. Cells were counted laterally to this line for quantification of DLS ChAT interneuron ablation (Fig. 3B ) and medially to it for quantification of DMS ablation (Fig. 3E) . Of note, ablation remained statistically significant when cells were counted across the entire striatum, although the absolute difference between the ablated and control condition was reduced because of the inclusion of nontargeted subregions. Fig. S4 . Prepulse inhibition in DLS-and DMS ChAT-ablated mice. PPI was tested as previously described (5, 7) using three prepulse intensities. (A) There was no significant PPI deficit after DLS ChAT interneuronal ablation. n = 6 DLS ablated, 5 control; RM-ANOVA: main effect of intensity, F(2,18) = 3.7, P = 0.047; main effect of group, F(1,9) = 0.87, P = 0.38; intensity × group interaction F(2,18) = 0.82, P = 0.46. The nominally lower PPI in the ablated group resulted from two animals with very low PPI in this group; ablation in these two animals did not differ in either location or density from the rest of the group. (B) There was no deficit in PPI after DMS ChAT interneuronal ablation. n = 7 DMS ablated, 6 control; RM-ANOVA: main effect of intensity, F(2,22) = 7.7, P = 0.003; main effect of group, F(1,11) = 0.25, P = 0.63; intensity × group interaction, F(2,22) = 1.4, P = 0.27. Movie S1
